Clinical Features and Treatment Outcomes among Children with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Study in a Tertiary Referral Hospital

Table 3

Treatment and treatment outcomes of patients with Stevens-Johnson syndrome and overlap-toxic epidermal necrolysis.

	SJS, N = 20	Overlap-TEN, N = 16	Overall, N = 36	P value
Treatment, N (%)
Specific treatment	16 (80.0)	75.0	77.8	0.720
Supportive treatment only	4 (20.00)	25.0	22.2	0.720
Duration of hospital stay (d) (mean ± SD)	7.1 ± 4.1	17.7 ± 13.1	11.8 ± 10.6	<0.001
Comorbidities/short-term complication, N (%)
Skin	10 (50.0)	16 (100.00)	26 (72.2)	0.001
Dyspigmentation	10 (50.0)	16 (100.00)	26 (72.2)	0.001
Nail change	0	4 (25.00)	4 (11.1)	0.018
Eye	10 (50.0)	14 (87.5)	24 (66.7)	0.018
Conjunctivitis	8 (40.0)	9 (56.3)	17 (47.2)	0.332
Corneal epithelial defects	2 (10.0)	4 (25.0)	6 (16.7)	0.230
Synechiae/symblepharon	2 (10.0)	4 (25.0)	6 (16.7)	0.248
Pseudomembrane	3 (15.0)	3 (18.8)	6 (16.7)	0.764
Superinfection	3 (15.0)	7 (43.8)	10 (27.8)	0.053
Vaginal adhesion	0	3 (18.8)	3 (8.3)	0.043
Pneumonia	1 (5.0)	1 (6.2)	2 (5.6)	0.871
Pancreatitis	0	1 (6.2)	1 (2.8)	0.257
Adrenal insufficiency	0	1 (6.2)	1 (2.8)	0.257
Long-term sequel, N (%)
Skin	5 (25.0)	14 (87.5)	19 (52.8)	0.001
Eye	4 (20.0)	9 (56.3)	13 (36.1)	0.042
GI (transaminitis)	2 (10.0)	6 (37.5)	8 (22.2)	0.124
Recurrence, N (%)	1 (5.0)	0	1 (2.8)	0.364
Mortality rate, N (%)	0	0	0

Significant values are shown in bold.